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ABSTRACT 
 
Standardized uptake value ratios (SUVR) are used for relative quantification of 18F-
Florbetaben (FBB) scans. Cerebellar cortex can be used as reference region for 
quantification. However, cerebellar amyloid-beta (Aplaques may be present in 
Alzheimer disease (AD). The aim of this study was to assess the influence of Apathology, 
including neuritic, diffuse plaques, and vascular deposits, in FBB SUVR, when using 
cerebellum as the reference.  
Methods: Neuropathological assessment of frontal, occipital, anterior and posterior 
cingulate cortices and cerebellar cortex from 87 end of life patients (64 AD, 14 other 
dementia, 9 non-demented aged volunteers; 80.4±10.2 yrs.) who underwent a FBB positron 
emission tomography (PET) before death was performed using immunohistochemistry for 
Aβ plaques and vascular deposits and the Bielschowsky method to demonstrate neuritic 
plaques. The lesions were rated as as absent (none, sparse) or present (moderate, frequent). 
Mean cortical SUVRs were compared among cases with different cerebellar Aloads.  
Results: None of the 83 evaluable cerebellar samples showed frequent diffuse A or 
neuritic plaques, 8 samples showed frequent vascular Adeposits. Diffuse Aβ plaques 
were rated as absent in n=78 samples (94%) and as present in n=5 samples (6%). Vascular 
A was rated as absent in 62 samples (74.7%) and as present in 21 samples (25.3%). No 
significant differences in the cerebellum SUVs were found among cases with different 
amounts or types of A deposits in the cerebral cortex. Both diffuse and neuritic plaques 
were found in the cerebral cortex of 26-44 cases. No significant SUVR differences were 
found in these brains, which showed different cerebellar A loads.  
Conclusions: The effect of cerebellar plaques in cortical FBB SUVRs appears to be 
negligible even in advanced stages of AD with a higher cerebellar Aβ load. 
 
Key words: Alzheimer disease, florbetaben, positron-emission tomography 
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INTRODUCTION 
Histopathological confirmation of the in-vivo detection of amyloid-beta (Aplaques by 
means of 18F-Florbetaben PET imaging supports the use of this tracer as a biomarker for 
identifying brain A burden in clinical practice (1). Visual assessment, using a systematic 
methodology developed for this amyloid PET tracer, has shown high accuracy in the 
identification of positive and negative scans (2,3).  However, potential subtle changes in 
Aburden over time may not be apparent by visual inspection of the images. Thus, 
quantitative analysis has been found necessary for longitudinal observational studies and 
interventional trials when change in amyloid burden measured by PET serves as a treatment 
end point (4,5). 
The main quantification used in brain A PET imaging is the standardized uptake 
value ratio (SUVR), a relative measurement defined as the ratio of SUV (% injected 
dose/body weight) in the target region over the SUV in the reference region. There are 
theoretical requirements for a reference region to be chosen, such as to have similar cellular 
and blood flow characteristics as the target region and to be devoid of specific binding sites 
(i.e. to be amyloid-free), thus having the same non-displaceable activity (free+nonspecific 
binding) as the target region (4). The cerebellar cortex is commonly used as a reference 
region for FBB quantification (4,6). This region fulfills all the requirements, except that it 
may contain A plaques in patients with the most advanced stage of AD (7) and in some 
types of familial AD (8). In these patients, the increase of specific A binding in the 
cerebellum might lead to an underestimation of the cortical SUVR measurements of A 
plaque load. This possibility has raised some concern about relying on this area as a 
reference region (4,8). Correlations of in vivo FBB PET scan SUVR quantification with 
post-mortem neuropathological assessments of cerebral cortical and cerebellar Aplaques 
would allow this concern to be investigated. Therefore, a post hoc analysis of a FBB PET 
assessment correlation with pathology from a phase 3 clinical trial was performed in order 
to assess the influence of cerebellar amyloid pathology, including neuritic plaques and 
diffuse A plaques as well as vascular A deposits, in FBB SUVR when using the 
cerebellar cortex as reference region.  
 
METHODS 
Subjects 
 FBB PET scans and brain tissue samples from a total of 87 end of life patients 
included in a Phase 3 study, who underwent a PET scan during life and subsequent 
neuropathological assessment at autopsy, were included in the analysis. In brief, n=64 
patients were diagnosed with AD (79.6±9.9 yrs), n=14 of other forms of dementia 
(88.2±9.3 yrs), and n=9 were non-demented aged volunteers (77.1±11.4 yrs) This study 
was conducted in accordance with the Declaration of Helsinki. Approvals by regulatory 
authorities and ethics committees were obtained (1). 
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FBB PET 
FBB PET images were acquired 90–110 minutes after intravenous injection of 300 
MBq ± 20% florbetaben according to a standardized acquisition and image-processing 
protocol (1). Three-dimensional volumetric T1-weighted brain magnetic resonance imaging 
data were also collected. 
Quantification was performed using the method described in Barthel et al. (2011) 
(6). A standardized volume of interest (VOI) template was applied to the spatially 
normalized gray matter PET image based on a gray/white/cerebrospinal fluid segmentation 
of the participant’s T1-weighted volumetric magnetic resonance imaging.  
SUVs were obtained from both cerebellar cortex and cerebral cortical regions using 
the corresponding segmented gray portion of the template VOI. The cerebral cortical 
regions included two regions likely to contain high numbers of A plaques, such as the 
frontal cortex and the posterior cingulate cortex, and two regions likely to contain lower 
numbers of A plaques, such as the occipital cortex and the anterior cingulate cortex. 
Cerebral cortical SUVRs were then calculated using the cerebellar cortex as the reference 
region. 
Neuropathology 
Sections for histological analysis were cut from formalin-fixed paraffin-embedded 
tissue blocks from 5 predefined brain regions of interest including 4 cortical regions 
(frontal cortex, occipital cortex, anterior cingulate gyrus and posterior cingulate 
gyrus/precuneus) and one cerebellar cortical region (for details see (1)). Analysis for the  
presence or absence of neuritic plaques and diffuse A plaques as well as vascular 
Adeposits, was performed by three experienced neuropathologists as previously 
described (1). 
Diffuse Aβ plaques and vascular Adeposits were assessed by 
Aimmunohistochemistry (monoclonal 6E10 Aβ antibody, Zytomed Systems, Berlin, 
Germany) and neuritic plaques were assessed by Bielschowsky silver stains (BSS) in 
sections from each tissue block. 
Both types of plaques and vascular Adeposits were quantified according to a 
semi-quantitative score, which was originally developed for neuritic plaques (9) using the 
categories none, sparse, moderate or frequent. In the absence of any other semi-quantitative 
scoring system for diffuse Aplaques and vascular Adeposits, the same scoring system 
was applied for these types of pathology, which in addition allowed for semi-quantitative 
comparison across pathology subtypes. Pathology was rated as absent when the scoring for 
each category (neuritic plaques, diffuse A plaques and vascular A deposits) was none or 
sparse, and rated as present when scoring was moderate or frequent. 
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Statistical analysis 
FBB mean cerebellar cortex SUVs and cerebral cortical SUVRs were compared 
among different cerebellar A scores by means of a two-way analysis of variance 
(ANOVA) using the cerebellar diffuse A plaques and the vascular A deposits as factors 
potentially influencing SUV and SUVRs.  Because of the negligible amount of neuritic 
cerebellar plaques found, these were not taken into account in the ANOVA analysis. 
 
RESULTS 
Cerebellar cortex pathology 
Results related to A pathology in the cerebellar cortex are summarized in Table 1. 
A total n=83 cases with a sample of cerebellar cortex were evaluable. Neuritic plaques were 
scored as none in all but one cerebellar sample, which was scored as sparse. Therefore, 
neuritic plaques were rated as absent in all samples. According to the semi-quantitative 
scoring system described above, diffuse A plaques were rated as absent in n=78 samples 
(94%) and as present in n=5 samples (6%), all with a moderate amount of pathology. No 
samples contained frequent diffuse A plaques in the cerebellum.  Vascular Awas the 
most frequently detected type of A deposit. It was rated as absent in 62 samples (74.7%), 
and as present in 21 samples (25.3%) (Table 1).  
From the total of 21 samples showing vascular Adeposits, vascular A was the 
only type of Apathology present in n=18 samples (86%), while n=3 (14%) samples also 
contained moderate diffuse Aplaques in the cerebellar cortex (molecular layer). On the 
other hand, 3 out of 5 (60%) of the samples with moderate diffuse Aplaques also 
contained vascular Adeposits (Fig. 1, Table 1).  The only sample with sparse neuritic 
plaques also contained both sparse diffuse Aplaques and moderate vascular Adeposits. 
FBB quantification and pathology 
Cerebellar SUVs ranged between 0.26 and 1.79 (0.90±0.32 (0.83, 0.97); mean±sd 
and 95% confidence intervals). No significant SUV differences were found in the cerebellar 
cortex among brains with none, sparse or moderate cerebellar A pathology (pdiffuse=0.49, 
pvascular=0.43) (Fig. 1). In subjects rated for presence of cerebral cortical plaques (i.e. 
moderate or frequent A diffuse and/or neuritic plaques, in 26-44 cases), who are the most 
likely to have A deposits in the cerebellum, cortical SUVRs ranged between 0.91-2.37 
(frontal cortex), 1.10-2.13 (occipital cortex), 0.83-2.49 (anterior cingulate cortex) and 0.95-
2.84 (posterior cingulate cortex). No significant SUVR differences among brains with 
different amounts of cerebellar A pathology (i.e. scores of none, sparse or moderate) were 
found (Table 2, Figs. 2 and 3). Neither the nature nor the amount of A deposits in the 
cerebellum had any effect on cortical SUVRs. When analyzing the full cohort of patients, 
including those with either the absence or presence of cortical A plaques, cortical SUVRs 
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ranged between 0.66-2.37 (frontal cortex), 1.07-2.13 (occipital cortex), 0.47-2.49 (anterior 
cingulate cortex) and 0.95-2.84 (posterior cingulate cortex). In the full cohort, the amount 
of cerebellar Apathology positively correlated with the amount of amyloid plaques in the 
cerebral cortex as measured using SUVRs (Table 2, Fig. 4). 
 
DISCUSSION 
To the best of our knowledge, this is the first study comparing post-mortem 
pathologically confirmed cerebellar A pathology with ante-mortem FBB PET scan 
quantification within the same subjects to investigate the appropriateness of the use of the 
cerebellum as a reference region. Neuropathological studies have shown that Ais present 
in the cerebellum only in the most advanced stage of AD, when other cerebral regions 
including the cortex are already severely affected (7).  Therefore, the potential influence of 
cerebellar A in cortical SUVR quantification was investigated in patients with cerebral 
cortical A plaques. This study showed that the potential binding of FBB to cerebellar 
amyloid does not influence the SUVR in cerebral cortical regions. Most of the cerebellar 
amyloid deposits were in form of either diffuse Aplaques and/or vascular A, which have 
been reported to influence the cerebral cortical SUVR measurements using FBB (10). 
However, in this study the cerebellar SUV was not influenced by either the amount or the 
type of A deposition, probably because of the relatively low levels of Adeposits 
detected in the cerebellum. This finding indicates that the signal from any potential FBB 
binding in the cerebellum will be small and is likely to fall within the margins of error in 
PET signal measurement, and will therefore not be detectable. Another possible 
explanation may be the morphological and immunocytochemical differences between the 
neuropathological lesions of AD in the cerebral cortex and cerebellum (11). As expected, 
the amount of cerebellar Adeposition assessed pathologically correlated positively with 
the cortical SUVRs in the full sample of patients; subjects without Adeposition in the 
cerebral cortex did not show A deposition in the cerebellum, and the higher the amount of 
cerebellar Adeposition, the higher the cerebral cortical SUVR.  
Cerebellar pathology in AD 
It is well established in the literature that A deposits can be found in the 
cerebellum in the patients with AD and Down syndrome. Cerebellar amyloid plaques were 
detected in “familial organic psychosis (Alzheimer’s type)” as early as 1934 (12) and the 
existence of diffuse Aplaques in the cerebellum has been noted with introduction and the 
increasingly widespread use of Aimmunohistochemistry (13-15). The presence of 
cerebellar Adeposits has been reported especially – but not exclusively - in familial forms 
of AD, e.g. in patients with APP and PSEN1 mutations (16,17), in severe early-onset cases 
of AD (15) and in the late stages of sporadic AD. In Braak and Braak´s neuropathological  
staging of AD, the presence of cerebellar pathology is only mentioned in stage C (18) and 
in the more recent analysis of the sequence of A deposition in the brain in AD by Thal et 
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al., the presence of cerebellar Adeposits is described in the final stage of the disease 
(Phase 5) (7).  
 The amount of diffuse A plaques and neuritic plaques detected in the cerebellum 
in our study is fully in keeping with earlier descriptions (13,15,19): While sparse neuritic 
plaques as determined by BSS were identified only in one case, diffuse A plaques in 
varying amounts were identified in 39 (= 47%) cases. Since the number of A deposits in 
most of these cases did not meet the criteria to be scored as moderate the pathology was 
overall rated as absent, while only 6% (n=5) of cases had moderate quantities of 
Apathology, which was rated as presentaccording to the agreed criteria for this study. A 
larger sample of cases with presence of cerebellar Apathology would have been desirable 
to investigate whether a subtle FBB uptake in the cerebellum may have any effects on 
cortical SUVR.   
 
Vascular A deposition was detected in 25.3% of the 83 evaluable cerebellar 
samples in this study. In the cerebellar samples from AD patients (n=60), vascular 
Adeposition was found in n=17 cases (28.3%), Thus, the overall frequency of cerebellar 
vascular A deposits in this sample is somewhat less than reported for some earlier series 
of AD patients (13,14,20), but still occurred in a significant portion of samples. This 
finding is not surprising, since the phase 3 clinical trial that provided the patients for this 
study included end-of-life patients only, often in advanced clinical stages of the AD (1). 
Therefore, this series of patients is considered representative of the late neuropathological 
stages of AD in the majority of cases. However, in the target clinical population for 
amyloid PET imaging for diagnostic purposes the cerebellum is likely to be devoid of 
Apathology, as the clinical population expected to undergo diagnostic PET imaging is 
considered likely to be in the early stages of AD and may include atypical cases of 
cognitive impairment with difficult diagnoses (21), in which the AD pathology may not be 
advanced.  
The nature and distribution of the Adeposited in the cerebellar samples in this 
study is fully in keeping with earlier descriptions (11,13). Most of the diffuse Aplaques in 
the cerebellum were present in the molecular layer, although in some AD cases diffuse 
Aplaques have been observed in the Purkinje cell and granular cell layers (13-17). It has 
been suggested that the pathology of cerebellar A plaques is similar, but not identical to 
the respective Adeposits in the cerebral cortex, as some of the accompanying elements of 
AD pathology including  neurofibrillary tangles and microglial activation appear either 
absent or much less common in the cerebellum (11,22). Thus, cerebellar A plaques have 
been considered to possibly represent an earlier form of plaque evolution or even an 
attenuated stage in the process of plaque maturation when compared to the Aplaques in 
the cerebral cortex in AD. These suggestions may reflect the observation that cerebellar 
pathology in AD is not as readily demonstrable by either classical neuropathological 
staining techniques or classical neuroimaging methods. 
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Cerebellum as the reference region in FBB amyloid PET 
Selection of the reference region in the brain has been emphasized as one of the 
most critical factors affecting A PET measurements (4). One of the reasons to select the 
cerebellar cortex for the first A PET studies with 11C-PIB was the finding that clearance of 
this tracer from the cerebellar gray matter is more similar to its clearance from the cerebral 
gray matter target regions than from cerebral white matter (23). Moreover, in the clinical 
population in whom the use of brain Aimaging is intended, the cerebellum is likely to be 
devoid of A in most patients, as described above. 11C-PIB retention in the cerebellum in 
familial AD has been reported (8), leading to the suggestion that the cerebellum may not be 
an appropriate reference region for 11C-PIB in subjects with likelihood of cerebellar 
Aplaques (24). However, to the best of our knowledge, no correlations between the in-
vivo 11C-PIB scans and cerebellar pathology post-mortem in the same individuals were 
performed in previous studies. No familial AD cases were included in this study, thus the 
potential effect of FBB binding to cerebellar Ain the SUVR in these cases remains 
unknown. However, A PET imaging has been considered to be inappropriate when the 
diagnosis is based solely “on a positive family history of dementia or presence of 
Apolipoprotein E (APOE)ε4” (21). The results from our study show that FBB retention in 
the cerebellum (SUV) is not affected by the presence of cerebellar A pathology in end-of-
life patients (including advanced AD cases), and that when using FBB as A PET tracer the 
potential influence of cerebellar A deposits on cortical SUVRs when the cerebellar 
cortical gray matter is the reference region is negligible. From a biological perspective, the 
cerebellar cortex is the most appropriate reference region for A PET quantification, and 
this study supports its use in FBB A PET scans.  
In the absence of direct PET and pathology correlation studies to address the 
influence of cerebellar A pathology in the cortical SUVR when using other A PET 
tracers, the search for alternative reference regions to the cerebellum for each amyloid PET 
tracer has been the subject of recent active research. The pons and the subcortical white 
matter are the two main brain regions studied as an alternative reference region to the 
cerebellum. (25)(7,26). Whereas the pons has similar blood flow characteristics to the 
cerebral cortex (27), supporting its use as a reference region in brain 18F-
Fluorodeoxyglucose and 18F-Flutemetamol PET scans, this is not the case for the 
subcortical white matter (23,28). The pharmacokinetics of 11C-PIB differs in the pons (and 
subcortical white matter) when compared with cerebral cortical areas in subjects without 
brain Adeposition (23). Therefore, 11C-PIB pharmacokinetics in the pons may not 
adequately represent the cerebral cortical tissue kinetics of nonspecifically bound and free 
11C-PIB. Nevertheless, SUVRs using the pons as the reference region have been used for 
11C-PIB when there is retention in the cerebellum (24). The presence of subcortical white 
matter abnormalities with different flow and cellular characteristics across aged subjects 
such as white matter vascular pathology is frequent in the elderly population (29-31), and 
therefore the SUV in this region is not stable, making the rationale for exploring the 
subcortical white matter as a reference region for APET quantification questionable. 
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Potential issues arising from the use of the cerebellar cortex as the reference region 
include technical factors. In PET centers with little experience in brain PET scans and head 
positioning, the proximity of the cerebellum to the edge of the scanner field of view may 
lead to signal noise and truncation (4). The small VOI sizes, which contain low counts, may 
lead to statistical noise and high variability of measurements. This may explain in part the 
rationale for attempting to use the subcortical white matter as the reference region in 
patients followed longitudinally with 18F-Florbetapir (32). However, the use of the whole 
cerebellum (including gray and white matter) in the VOI would increase the statistical 
counts in the reference region. In a recent study comparing different reference regions 
across different amyloid tracers (18F-Flutemetamol, n=258; 18F-Florbetapir n=184; and 18F-
Florbetaben n=211), in different clinical conditions, in patients with different cerebral A 
status, and across time, found the cerebellar gray matter as the most stable reference region 
across the examined conditions for FBB, but not for 18F-Flutemetamol or 18F-Florbetapir, 
where a composite of the subcortical white matter+pons and the subcortical white matter  
were reported as the most stable reference regions respectively (33). Comparison of 
different reference regions using FBB in longitudinal studies is not the objective of the 
current study. However, our results with FBB are consistent with the findings of this study 
(33), reinforcing the use of the cerebellar cortex as an appropriate reference region for this 
tracer. In a cross-sectional study comparing FBB SUVR results across the cerebellar cortex, 
whole cerebellum, pons, and white matter as reference regions showed no significant 
differences in effect sizes, correlation coefficients, test-retest variability or intra-class 
correlation coefficients across the different reference regions (34). Altogether, these results 
show that FBB quantification is very robust, and that the cerebellar cortex is the most 
appropriate reference region for FBB from both theoretical and biological perspectives, and 
can be used in any clinical setting in which this amyloid tracer is employed. 
 
CONCLUSIONS 
This study addresses for the first time the potential influence of the presence of A 
pathology in the cerebellum in FBB quantification, by means of a within-subject PET and 
pathology correlation design in an end-of-life patient population, which included cases with 
advanced stages AD. The results show that the effect of cerebellar Apathology in FBB 
SUVR quantification is negligible, even in subjects with a high A load in the cerebral 
cortex, thus supporting the use of cerebellar cortical gray matter as the reference region for 
FBB SUVR quantification.  
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TABLES 
  
Table 1. Cerebellar cortex pathology results. 
 
Vascular A deposits   
Absent  Present   
62  21   
none  sparse  moderate  frequent  Total 
Diffuse 
A 
plaques 
Absent  78  none  25  14  3  2  44 sparse  8  13  8*  5  34 
Present  5  moderate  1  1  2  1  5 frequent  0  0  0  0  0 
      Total  34  28  13  8  83 
Numbers refer to number of samples with the corresponding pathology finding. *One subject in this group showed also 
sparse neuritic plaques. 
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Table 2.  FBB SUVRs for each cerebral cortical region among different cerebellar Adeposits and scores 
(mean ± sd and 95% confidence interval), and statistical comparison results. 
SUVR=standardized uptake value ratio taking the cerebellar cortex as reference region; ANOVA= analysis of variance; Ant. Cing.= 
Anterior cingulate; Post. Cing.=Posterior cingulate   
   Cerebellar Ascores ANOVA 
 Cerebral 
region (n) 
Cerebellar 
Adeposits Absent Sparse Moderate Frequent pdiffuse pvascular 
SUVR (full 
sample) 
Frontal 
cortex 
(83) 
Diffuse 
plaques 
1.36±0.35 
(1.29,1.43) 
1.70±0.33 
(1.62,1.77) 
1.82±0.29 
(1.76,1.89) - <10-4 0.003 
Vascular 1.31±0.35 (1.23,1.38) 
1.66±0.34 
(1.56,1.74) 
1.66±0.33 
(1.59,1.73) 
1.77±0.24 
(1.72,1.82) 
Occipital  
cortex 
(82) 
Diffuse 
plaques 
1.44±0.21 
(1.40,1.49) 
1.66±0.24 
(1.61,1.71) 
1.69±0.26 
(1.64,1.75) - <10-4 0.001 
Vascular 1.41±0.21 (1.36,1.46) 
1.63±0.21 
(1.59,1.68) 
1.65±0.30 
(1.58,1.71) 
1.66±0.19 
(1.62,1.70) 
Ant. Cing. 
cortex 
(82) 
Diffuse 
plaques 
1.37±0.40 
(1.29,1.46) 
1.74±0.38 
(1.66,1.82) 
1.86±0.31 
(1.80,1.93) - <10-4 0.03 
Vascular 1.35±0.37 (1.27,1.43) 
1.65±0.45 
(1.56,1.75) 
1.67±0.43 
(1.58,1.77) 
1.91±0.18 
(1.87,1.95) 
Post. 
Cing.   
cortex  
(82) 
Diffuse 
plaques 
1.59±0.39 
(1.51,1.67) 
1.87±0.37 
(1.79,1.95) 
1.86±0.24 
(1.81,1.92) - 0.004 0.13 
Vascular 1.56±0.37 (1.48,1.64) 
1.80±0.39 
(1.72,1.89) 
1.81±0.43 
(1.72,1.90) 
1.96±0.22 
(1.91,2.01) 
SUVR 
(subsample) 
Frontal  
cortex 
(44) 
Diffuse 
plaques  
1.64±0.34 
(1.54,1.74) 
1.77±0.29 
(1.69,1.85) 
1.73±0.24 
(1.66,1.80) - 0.47 0.83 
Vascular 1.64±0.33 (1.54,1.74) 
1.74±0.32 
(1.65,1.84) 
1.75±0.26 
(1.67,1.83) 
1.79±0.28 
(1.71,1.87) 
Occipital  
cortex 
(41) 
Diffuse 
plaques 
1.67±0.21 
(1.60,1.73) 
1.68±0.23 
(1.61,1.75) 
1.60±0.16 
(1.55,1.65) - 0.77 0.08 
Vascular 1.50±0.22 (1.43,1.56) 
1.68±0.19 
(1.62,1.74) 
1.74±0.23 
(1.67,1.81) 
1.74±0.17 
(1.68,1.79) 
Ant. Cing.   
cortex  
(26) 
Diffuse 
plaques 
1.73±0.39 
(1.58,1.88) 
1.77±0.36 
(1.63,1.90) 
1.74±0.18 
(1.67,1.81) - 0.97 0.57 
Vascular 1.77±0.16 (1.70,1.83) 
1.72±0.48 
(1.54,1.91) 
1.63±0.18 
(1.56,1.70) 
1.92±0.21 
(1.84,2.00) 
Post. 
Cing.   
cortex  
(32) 
Diffuse 
plaques 
1.91±0.44 
(1.77,2.06) 
1.94±0.34 
(1.82,2.06) 
1.79±0.20 
(1.72,1.86) - 0.78 0.96 
Vascular 1.90±0.42 (1.76,2.05) 
1.90±0.43 
(1.75,2.05) 
1.89±0.29 
(1.79,1.99) 
1.98±0.26 
(1.89,2.07) 
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Figure 1. FBB cerebellar SUV distribution according to the different cerebellar diffuse Aβ 
plaque loads. None and sparse scores were rated as absence of Aβ plaques. White dots: 
subjects with no vascular A in the cerebellum; black dots: subjects with vascular A in the 
cerebellum.  
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Figure 2.  FBB SUVR distribution in the four cortical regions studied according to the 
different cerebellar diffuse Aβ plaque loads in subjects with presence of cerebral cortical 
Aβ plaques. None and sparse scores were rated as absence of Aβ plaques. White dots: 
subjects with no vascular A in the cerebellum; black dots: subjects with vascular A in the 
cerebellum.  
 
 
 
  
by Universitaet Leipzig on July 12, 2016. For personal use only. jnm.snmjournals.org Downloaded from 
 19 
 
Figure 3. Representative FBB PET images in a subject with sparse diffuse A plaques in 
the cerebellum and frequent diffuse Aplaques in all cortical regions, with moderate 
neuritic plaques in the frontal cortex and moderate vascular A in the occipital cortex. 
SUVR(frontal cortex)=2.08; SUVR(occipital cortex) = 1.50; SUVR(anterior cingulate 
cortex)=2.26; SUVR(posterior cingulate cortex)=2.22.
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Figure 4. FBB SUVR distribution in the four cortical regions studied according to the 
different cerebellar diffuse Aβ plaque loads in the full sample of subjects rated with either 
absence or presence of cerebral cortical Aβ plaques. None and sparse scores were rated as 
absence of Aβ plaques. White dots: subjects with no vascular A in the cerebellum; black 
dots: subjects with vascular A in the cerebellum.  
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